Effects of Sacubitril/Valsartan versus Irbesartan on Urine Tubular Biomarkers in Chronic Kidney Disease: Findings from the UK HARP-III Trial
American Journal of Nephrology · 07.05.2026 · 1-4
DOI: 10.1159/000552348 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Nephrology, online erschienen am 07.05.2026. Verfasst von Michelle A Goonasekera und 17 weiteren Autor:innen. Beteiligte Einrichtung: Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Ox…. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Sacubitril/valsartan shows benefits in heart failure and may have kidney protective effects. Its impact on kidney tubular health in chronic kidney disease (CKD) remains unclear. We evaluated the effects of sacubitril/valsartan on urinary markers of tubular dysfunction and injury in UK Heart and Renal Protection-III (HARP III, ISRCTN:11958993).
Methods
Urine tubular biomarkers were measured at baseline, 3 and 6 months using first morning void or spot urine samples among 411 participants from UK HARP III. A mixed model repeated measures approach was used to quantify the study average effect of treatment on the urine biomarkers.
Results
Compared to allocation to irbesartan, allocation to sacubitril/valsartan reduced neutrophil gelatinase-associated lipocalin (NGAL), a marker secreted in the distal tubules after ischemia and reperfusion, by 18% (95% CI: −32% to −1%). No significant changes were observed for the other biomarkers, and there was no evidence of effect modification by key baseline characteristics across all biomarkers studied.
Conclusion
In UK HARP-III, sacubitril/valsartan reduced urinary NGAL compared with irbesartan but did not affect other tubular biomarkers of injury, ischemia, and fibrosis, suggesting limited tubular benefits, consistent with no observed effect on kidney function.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
- Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Wolfson Laboratory, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
- College of Life Sciences, University of Leicester, Leicester, UK.
- Department of Nephrology, University Hospitals of Leicester NHS Trust, Leicester, UK.
- British Heart Foundation Glasgow, Glasgow, UK.
Zitieren
APA
Goonasekera, M. A., Malijan, G. B., Sardell, R. J., Staplin, N., Storey, B. S., Chapman, D., Hill, M., Moffat, S., Al-Mohammad, A., Zhu, D., Brunskill, N. J., McMurray, J. J. V., Taal, M. W., Herrington, W. G., Landray, M. J., Baigent, C., Haynes, R., & Judge, P. K. (2026). Effects of Sacubitril/Valsartan versus Irbesartan on Urine Tubular Biomarkers in Chronic Kidney Disease: Findings from the UK HARP-III Trial. American Journal of Nephrology, 1-4. https://doi.org/10.1159/000552348
Vancouver
Goonasekera MA, Malijan GB, Sardell RJ, Staplin N, Storey BS, Chapman D, et al. Effects of Sacubitril/Valsartan versus Irbesartan on Urine Tubular Biomarkers in Chronic Kidney Disease: Findings from the UK HARP-III Trial. American Journal of Nephrology. 2026:1-4. doi:10.1159/000552348
BibTeX
@article{Goonasekera2026,
author = {Goonasekera, Michelle A and Malijan, Greco B and Sardell, Rebecca J and Staplin, Natalie and Storey, Benjamin S and Chapman, Daniel and Hill, Michael and Moffat, Stewart and Al-Mohammad, Abdulrahman and Zhu, Doreen and Brunskill, Nigel J and McMurray, John J V and Taal, Maarten W and Herrington, William G and Landray, Martin J and Baigent, Colin and Haynes, Richard and Judge, Parminder K},
title = {Effects of Sacubitril/Valsartan versus Irbesartan on Urine Tubular Biomarkers in Chronic Kidney Disease: Findings from the UK HARP-III Trial},
journal = {American Journal of Nephrology},
year = {2026},
pages = {1--4},
doi = {10.1159/000552348}
}
EUVIMED